Email
Print
Autoimmune Drugs & Disease Management Market - Forecast(2023 - 2028)
Autoimmune Drugs & Disease Management Market Overview
Autoimmune Drugs & Disease Management Market Size is
estimated to reach $172.3 billion by 2027, and it is poised to grow at a CAGR
of 11.8% over the forecast period of 2022-2027. Autoimmune diseases decrease
the body’s ability to fight foreign agents, thereby allowing the body to reach
in an unfavorable way, which more often than not is life-threatening. It is
identified that there are more than 80 different types of auto-immune disorders
amongst which multiple sclerosis, IBS, lupus, type-1 diabetes, psoriasis,
rheumatoid arthritis and others are the most common forms of the following
ailment. New mechanism biologics, novel oral agents and even biosimilars are
supporting the overall autoimmune disease market size, growth and penetration
of the Autoimmune Drugs & Disease Management Industry in the forecast period
of 2022-2027.
Autoimmune Drugs & Disease Management Market Report Coverage
The report: “Autoimmune Drugs & Disease Management
Market Forecast (2022-2027)" by IndustryARC, covers
an in-depth analysis of the following segments of the
Autoimmune Drugs & Disease Management Market.
By Drug Class Type: Anti-inflammatory,
Anti-hyperglycaemic, NSAIDs, Interferons and Others.
By Indication: Rheumatic Disease, Multiple
Sclerosis, IBD, Type-1 Diabetes and Others.
By Sales Channel: Hospital Pharmacies, Drug
Store & Retail Pharmacy and Online Stores.
By Geography: North America (the U.S., Canada, and
Mexico), Europe (Germany, United Kingdom (UK), France, Italy, Spain, Russia
and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia
and New Zealand and Rest of Asia Pacific), South America (Brazil, Argentina,
Chile, Colombia and Rest of South America) and Rest of the World (the Middle East
and Africa).
Key Takeaways
- Geographically, Autoimmune Drugs & Disease Management in North America held a dominant market share in 2021. It is owing to the tremendous healthcare costs present in regions such as the U.S. Moreover, the healthcare facilities along with disease pertinent knowledge and treatment propel the market.
- The rising prevalence of autoimmune diseases along with growing research and development activities by emerging technologies has been a recognized autoimmune drug industry driver. However, inadequate funding and the advent of alternative technologies impede the market growth.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Autoimmune Drugs & Disease Management Market Report.
Autoimmune Drugs & Disease Management Market - by Indication
Autoimmune Drugs & Disease Management Market based on
indication can be further segmented into Rheumatic Disease, Multiple Sclerosis,
IBD, Type-1 Diabetes, and Others. Multiple Sclerosis held a dominant market
share in the year 2021. As per NCBI 2021, the estimated number of people with
MS worldwide increased to 2.8 million in 2020. The estimate is 30% higher
than in 2013 from 2020. The 2020 global prevalence is 35.9 per 100,000 people.
However, IBD is estimated to be the fastest growing with a CAGR of 12.5% over
the forecast period of 2022-2027. It is owing to the rapidly growing geriatric
population and a higher prevalence of the disease in the said age group. As per
Karger, up to 35% of patients with IBD are aged 60 or greater.
Autoimmune Drugs & Disease Management Market - by Sales Channels
Autoimmune Drugs & Disease Management Market based on
sales channels can be further segmented into Hospital Pharmacies, Drug stores
& Retail pharmacies, and Online Stores. Drug Stores & Retail Pharmacies
held a dominant market share in the year 2021. It is owing to a dominant
presence across the countries and regions, which allows convenience and owing
to digitization, the dispensing counters are highly modernized which has
allowed the following segment to hold the market share. As per Commonwealth
Fund, 2021, nearly 60,000 retail pharmacies exist in the U.S. However, online
stores are estimated to be the fastest-growing with a CAGR of 12.9% over the
forecast period of 2022-2027. The higher convenience offered by online
pharmacies continues to drive sales for various medicine dispensations.
Autoimmune Drugs & Disease Management Market - by Geography
Autoimmune Drugs & Disease Management Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. The autoimmune drugs & disease management market in North America held a dominant market share of 42% in 2021. This is due to the rising prevalence of autoimmune diseases and the increased presence of government programs such as the Patient Protection Act and the Affordable Care Act, which have been a boon for the autoimmune drugs & disease management market in the US. As per the National Institute of Health Estimates, the annual cost to treat auto-immune disease will touch 100 billion in the United States within certain years. However, Asia-Pacific is estimated to be the fastest-growing region with a CAGR of XX% over the forecast period of 2022-2027. It is owing to a rising geriatric population in developed countries such as China and Japan. Importantly, the autoimmune drugs & disease management market in MEA (the Middle East and Africa) carries the extreme potential for marketers owing to a growing base of various humanitarian services post-COVID-19.
Autoimmune Drugs & Disease Management Market Drivers
Rising Number of Autoimmune Diseases along with the Tremendous Increase in the Knowledge of Autoimmune Disease Management Propels the Market Growth.
The prevalence of auto-immune
diseases has been on a rise for over a decade primarily owing to a declining
standard of living and other materialistic habits. As per John Hopkins Medicine
Pathology, the overall prevalence of all autoimmune diseases affects nearly 3%
of the U.S. population or nearly 10 million people. Autoimmune diseases present
with a clear gender bias with a greater prevalence amongst women, occurring at
a rate of 2 to 1, as per the study published in NCBI, 2021.
Emerging Technologies and Research Along with Increased Automation in the Sphere of Biotech Pharma have Allowed the Market to Propel.
Targeted Cell-Based Therapy has been receiving utmost heed
within the field of medical science owing to its tremendous potential for
treating autoimmune diseases. As per a testimonial from research conducted in
St Anna Children’s Cancer Research, scientists discovered a key building block
in immune cells that is relevant in the context of autoimmune diseases. This
enables the dendritic cells to increase the immunotolerance of the T cells and
prevent them from attacking the body's own structures. For example, as per a
Neurology Publication of 2022, the estimated total economic burden for multiple
sclerosis in the U.S. was gauged at $85.4 billion with 63.3 billion in direct
medical costs.
Autoimmune Drugs & Disease Management Market Challenge
The Heightened Costs Associated with Treating Autoimmune Diseases along with the Non-Availability of the Right Treatments Hinder the Market Growth.
It is identified that within the developing countries there
are inadequate funds to flourish adequate adoption and setting up of autoimmune
disease management and drugs. Additionally, the cost associated with treating
autoimmune drugs is critically high and the underdeveloped region of the world
continues to struggle against the following. Further, as per Connect Immune
Research, the cost for just three autoimmune diseases costs £13 billion per year,
significantly impeding the autoimmune drugs & disease management industry in the UK.
Autoimmune Drugs & Disease Management Industry Outlook
Product launches, mergers and acquisitions, joint ventures
and geographical expansions are key strategies adopted by players in the
Autoimmune Drugs & Disease Management market. The top 10 companies in the
Autoimmune Drugs & Disease Management market are:
1. Abbott Laboratories
2. AbbVie Inc.
3. Amgen Inc.
4. AstraZeneca
5. Roche Ltd.
6. Johnson and Johnson
7. Novartis AG
8. Pfizer Inc.
9. UCB S.A.
10. Dr Reddy Laboratories.
Recent Developments
- In August 2022, Clene Nanomedicine chalked up a win for its gold nanocrystal suspension to treat multiple sclerosis. The oral therapy CNM-Au8 is currently being tested to treat amyotrophic lateral sclerosis, Parkinson’s disease and MS. The study in question was assessing whether CNM-Au8 could improve visual function and bodily coordination in MS patients over 48 weeks.
- In August 2022, a newer form of IL-6 or anti-interleukin 6 named olokizumab was termed equivalent to the existent adalimumab (Humira) for rheumatoid arthritis. The following medication is for RA patients who needed to be set up from methotrexate monotherapy.
- In March 2021, FDA approved a new medication for Multiple Sclerosis. The new medication, Ponvory, is a once-daily oral treatment. It’s been shown to reduce annualized relapse rates and new brain lesions in people with MS.
Relevant Titles
Report Code- HCR 0298
Report Code- HCR 0391
Report Code- HCR 0322
For more Lifesciences and Healthcare Market reports, please click here